Compare Danaher Corporation (DHR) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Huntington Bancshares Incorporated — how do they compare? Danaher Corporation trades at $200 (market cap $140.88B), while Huntington Bancshares Incorporated trades at $17.97 (market cap $36.18B). The key difference: Danaher Corporation is far larger — about 3.9× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| DHR | HBAN | |
|---|---|---|
Market Cap | $140.88B | $36.18B |
Sector | Health | Financials |
52-Week High | $242.05 | $19.27 |
52-Week Low | $161.91 | $15.02 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Huntington Bancshares (HBAN) trades at $17.93, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, and maintains a net income margin of 25.13%. Recent news highlights expansion in Texas and a fintech partnership award. Analyst consensus is a Buy with a $20.25 price target, suggesting potential upside.
HBAN presents a favorable outlook with earnings growth potential, supported by strategic acquisitions and solid fundamentals. Risks include integration challenges from recent M&A and competitive pressures in regional banking. The stock's current valuation below consensus target indicates room for appreciation, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
